Pathway to Cures

Pathway to Cures operates as a venture philanthropy fund, strategically investing in the development of transformational therapies and technologies. The organization's core focus is on early-stage biotechnology, pharmaceutical, medical device, and diagnostic companies dedicated to addressing all inheritable blood disorders, aiming to bridge critical funding gaps within this specialized sector. Its systematic approach involves identifying and backing promising innovations to accelerate their path to market.

The National Bleeding Disorders Foundation (NBDF) established Pathway to Cures in 2022, recognizing a significant need to catalyze research and development for inheritable blood conditions. This initiative emerged from the NBDF's long-standing dedication, dating back to its founding in 1948, to improve the lives of individuals affected by these disorders, underscoring a proactive shift towards direct investment in groundbreaking solutions.

Pathway to Cures primarily engages with early-stage companies, providing essential capital and strategic guidance to advance novel treatments. The organization's long-term vision is to significantly accelerate the availability of cures and improve health outcomes for people living with inheritable blood and bleeding disorders, fostering an ecosystem where innovative therapeutic solutions can thrive and reach patients.